When patients understand their inherited risk for cancer, they’re empowered to take action—often before cancer has a chance to take hold.

In this second episode of our Bringing Precision Medicine to Every Patient series, host Karan Cushman is joined by two trusted experts, Ellen Matloff and Dr. Angella Charnot-Katsikas. Together, they provide clear, practical guidance on how patients and clinicians can identify inherited cancer risk early—and take steps to address it.

Whether you’re a patient wondering where to begin, or a provider navigating limited time and resources, this episode delivers clear takeaways to help you move from uncertainty to informed action.

It’s a timely reminder that precision medicine doesn’t begin with treatment—it begins with knowledge. And with the right tools and support, patients can take control of their health and rewrite the story for generations to come.

Ellen Matloff is a nationally recognized genetic counselor, founder and CEO of My Gene Counsel, and a leading voice in digital health and patient-centered genomics. She founded and led the Yale Cancer Genetic Counseling Program and was a plaintiff in the landmark Supreme Court case that overturned gene patenting.

Dr. Angella Charnot-Katsikas is Chief Medical Officer at Palmetto GBA and a molecular diagnostics expert who helps guide coverage decisions through her work in precision medicine policy.

They share compelling stories that bring the science to life. Ellen reflects on one of her first BRCA1-positive patients—a healthy young mother who chose preventive surgery based on a powerful family history of cancer and a determination to break the cycle. Dr. Katsikas offers her own experience as both a pre-vivor and survivor, whose early diagnosis was only possible because of proactive testing and screening guided by her family history.

The episode also explains why many patients still miss these opportunities—due to limited awareness, inconsistent risk assessments, and systemic barriers in access. The guests highlight the limitations of consumer tests like 23andMe and the critical role of genetic counselors in interpreting results and guiding decisions.

They offer actionable strategies for integrating family history collection and risk assessment into routine care, including the use of digital tools in busy or resource-limited settings. Reimbursement challenges are discussed, alongside encouraging progress toward making precision medicine standard of care.

Special thanks to our good friend Dr. Kashyap Patel and the No One Left Alone initiative for

collaborating with us on this series. Our goal with Bringing Precision Medicine to Everyone is to equip patients, caregivers and care teams with the knowledge and tools needed to deliver the best of modern cancer care–no matter where a patient lives.